The FXR agonist obeticholic acid is currently in a phase III clinical trial for NASH treatment (NCT02548351) after two different phase II studies in NAFLD or NASH patients indicated a positive effect on fibrosis (NCT00501592 and NCT01265498) [155,156]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.